---
title: Pulmonary Fibrosis After Severe COVID-19 Pneumonia
nct_id: NCT06423560
overall_status: COMPLETED
sponsor: IRCCS San Raffaele
study_type: OBSERVATIONAL
primary_condition: Pulmonary Fibrosis
countries: Italy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06423560.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06423560"
ct_last_update_post_date: 2024-05-21
last_seen_at: "2026-05-12T06:56:01.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pulmonary Fibrosis After Severe COVID-19 Pneumonia

**Official Title:** Evaluation of Pulmonary Fibrosis After Severe Interstitial Pneumonia Due to COVID-19 (SARS-CoV-2)

**NCT ID:** [NCT06423560](https://clinicaltrials.gov/study/NCT06423560)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 61
- **Lead Sponsor:** IRCCS San Raffaele
- **Conditions:** Pulmonary Fibrosis, COVID-19
- **Start Date:** 2020-03-01
- **Completion Date:** 2024-05-16
- **CT.gov Last Update:** 2024-05-21

## Brief Summary

Patients discharged after hospitalization for COVID-19 pneumonia were retrospectively selected by radiologically established criteria that at admission presented at chest computed tomography (CT) (i) normal lung parenchyma \<50% of total lung volume; and/or (ii) area of lung consolidation \> 10%. All At discharge and after 9 months, all subjects underwent cardiological evaluation, echocardiogram, pulmonary function tests (PFT) both atby 3 and by 12 months after discharge. Chest CT was performed by 12 months after discharge and chest CT. Specifically, the magnitude of pulmonary involvement between baseline and follow-up was considered the primary endpoint of this study. Secondary endpoints of the study were results of respiratory function testing, echocardiographic parametersparameters, and persistence of symptoms.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age ≥ 18
* Hospitalization for severe COVID-19 pneumonia
* Computed tomography during index hospitalization that showed: (i) normale lung parenchyma \< 50% of total lung volume and/or (ii) parenchymal consolidation \> 10%
* Cardiological and pneumological visit, echocardiography and pulmonary function test at 3 and 12 months from hospital discharge
* Computed tomography by 12 months from hospital discharge

Exclusion Criteria:

* Age \< 18
* Absence of previously cited test.
```

## Arms

- **Residual disease > 20% of the total lung volume was considered pathological at follow-up CT**
- **Residual disease < 20% of the total lung volume was considered pathological at follow-up CT**

## Interventions

- **Computed tomography** (RADIATION) — Follow-up computed tomography at 3-6 months and 12 months

## Primary Outcomes

- **The magnitude of pulmonary involvement** _(time frame: 12 months)_

## Secondary Outcomes

- **results of respiratory function testing** _(time frame: 12 months)_
- **echocardiographic parameters** _(time frame: 12 months)_
- **persistence of symptoms** _(time frame: 12 months)_

## Locations (1)

- IRCCS San Raffaele, Milan, Lombardy, Italy

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.irccs san raffaele|milan|lombardy|italy` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06423560.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06423560*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*